Drs Joseph Mikhael and Peter Voorhees discuss considerations for treating smoldering multiple myeloma, including recent ...

Recent headlines proclaim a ‘potential’ or ‘functional’ cure for multiple myeloma, but the fight against the disease must ...

We recommend that CTC should be routinely assessed and measured at diagnosis as part of risk evaluation,” study researchers wrote.

In the late-stage MajesTEC-3 trial, Tecvayli plus the subcutaneous formulation of J&J’s antibody drug Darzalex beat ...

Acute myeloid leukemia (AML), an aggressive and often fatal blood cancer, has long resisted a class of drugs called ...

The triplet regimen of berdomide, daratumumab (Darzalex), and dexamethasone has led to deepening responses in newly diagnosed, transplant-ineligible patients with multiple myeloma.

If the combination were to be approved, Tecvayli would expand out from its traditional role in fourth line treatment and ...

Tecvayli combined with Darzalex Faspro improves overall survival in relapsed/refractory multiple myeloma, Johnson & Johnson ...

Dr. Matthew Matasar discusses why stem cell transplant is still a standard, life-saving option in blood cancers and how CAR-T ...

Johnson & Johnson announces Tecvayli plus Darzalex Faspro combo regimen significantly improves PFS and overall survival versus standard of care: Raritan, New Jersey Saturday, Octo ...

First Phase 3 study (MajesTEC-3) of an investigational combination to show benefit in PFS and OS in relapsed/refractory multiple myeloma as early as second line ...

By combining proteasome inhibitors with a second drug that disables one of two backup survival pathways, the team was able to ...